Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: Lancet Oncol. 2015 Apr 1;16(5):541–549. doi: 10.1016/S1470-2045(15)70106-3

Figure 2. Patient Sample Flow Diagram.

Figure 2

Tree diagram showing outcome of tumor clonotype analysis of pretreatment biopsy and serum specimens. One hundred and ninety-eight pretreatment samples were analyzed for tumor clonotypes and 126 patients had identifiable clones. The time to progression and overall survival of 108 patients with and without detectable interim ctDNA at the end of cycle 2 (i.e. day 1 of cycle 3) were determined by a landmark analysis. Among 107 patients who achieved complete remission at the end of treatment, the hazard risk of developing clinical progression based on detection of ctDNA was calculated using a Cox proportional hazard model.